期刊
JOURNAL OF IMMUNOLOGY
卷 184, 期 7, 页码 3377-3385出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0903324
关键词
-
类别
资金
- National Institutes of Health [RO1DK65748, R21AI68746]
- University of Missouri, Columbia
- National Institute of General Medical Sciences [GM008396]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073542, R21AI068746] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065748, R01DK093515] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008396] Funding Source: NIH RePORTER
Recently, traces of double-positive FoxP3(+)ROR gamma t(+) T cells were identified and viewed as dual programming differentiation intermediates geared toward development into T regulatory or Th17 cells. In this study, we report that FoxP3(+)ROR gamma t(+) intermediates arise in the NOD mouse T cell repertoire prior to inflammation and can be expanded with tolerogen without further differentiation. Furthermore, FoxP3(+)ROR gamma t(+) cells express both CD62L and membrane-bound TGF beta and use the former to traffic to the pancreas and the latter to suppress effector T cells both in vitro and in vivo. The cells perform these functions as FoxP3(+)ROR gamma t(+) intermediates, despite being able to terminally differentiate into either FoxP3(+)ROR gamma t(-) T regulatory or FoxP3(-)ROR gamma t(+) Th17 cells on polarization. These previously unrecognized observations extend plasticity to both differentiation and function and indicate that the intermediates are poised to traffic to sites of inflammation and target diverse pathogenic T cells, likely without prior conditioning by effector T cells, thus broadening efficacy against autoimmunity. The Journal of Immunology, 2010, 184: 3377-3385.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据